Am J Health Syst Pharm. 2011;68(15):1419-1425. The short duration of activity of naloxone when the drug is administered as an i.v. bolus may limit its effectiveness for the management of OIP.
Purpose: Data collected from the Food and Drug Administration (FDA) under the Freedom of Information Act are presented to help clinicians understand the data prompting the black-box warning for ...
Jan. 13, 2025 — A new study found no changes in opioid outcomes among the general population with the states' passage of medical and recreational marijuana laws. However, the findings also show ...
SOUTHERN OCEAN COUNTY – Sea Change, a nonprofit with offices in Barnegat and West Creek, is making waves in assisting people with substance use challenges. Officially founded in January 2021 by ...
It is often used in conjunction with the opioid antagonist, naloxone., which blocks euphoric effects. Medication-assisted treatment (MAT) does not, by itself, cure addiction, but it allows people ...
On the other hand, campaigns have been less specific about their policy platforms this year than ever before, leading to the label that this ... overdose-reversal drug naloxone available over ...